BFA
BMRN icon

BlackRock Fund Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

BlackRock Fund Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$355M Buy
4,288,652
+239,180
+6% +$20.6M 0.07% 314
2016
Q3 		$375M Buy
4,049,472
+312,016
+8% +$29.4M 0.08% 262
2016
Q2 		$291M Buy
3,737,456
+54,123
+1% +$4.6M 0.06% 336
2016
Q1 		$304M Buy
3,683,333
+193,224
+6% +$15.7M 0.07% 302
2015
Q4 		$366M Sell
3,490,109
-345,791
-9% -$36.1M 0.08% 228
2015
Q3 		$404M Buy
3,835,900
+248,606
+7% +$33.2M 0.1% 174
2015
Q2 		$491M Buy
3,587,294
+203,545
+6% +$25.2M 0.12% 144
2015
Q1 		$422M Buy
3,383,749
+431,829
+15% +$45.8M 0.1% 188
2014
Q4 		$267M Buy
2,951,920
+5,012
+0.2% +$417K 0.07% 313
2014
Q3 		$213M Buy
2,946,908
+112,520
+4% +$7.39M 0.06% 357
2014
Q2 		$176M Sell
2,834,388
-9,771
-0.3% -$590K 0.05% 459
2014
Q1 		$194M Buy
2,844,159
+183,450
+7% +$13.5M 0.06% 396
2013
Q4 		$187M Buy
2,660,709
+123,939
+5% +$8.42M 0.06% 404
2013
Q3 		$183M Buy
2,536,770
+312,495
+14% +$20.8M 0.06% 364
2013
Q2 		$124M Buy
+2,224,275
New +$139M 0.05% 501

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock Fund Advisors's BMRN Position: Q4 2016 in Review

BlackRock Fund Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 5.9% in Q4 2016, buying an estimated $20.6M and bringing the position to 4,288,652 shares worth $355M. The position accounts for 0.07% of the portfolio, ranked #314.

BlackRock Fund Advisors first reported a position in BMRN in Q2 2013 and has held it in 15 quarters since. The position peaked at $491M in Q2 2015. 414 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

  • BlackRock Fund Advisors held 4,288,652 shares of BioMarin Pharmaceuticals worth $355M as of Q4 2016.
  • BlackRock Fund Advisors bought 239,180 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $20.6M.
  • BioMarin Pharmaceuticals made up 0.07% of BlackRock Fund Advisors's portfolio in Q4 2016, its #314 holding.
  • BlackRock Fund Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's BioMarin Pharmaceuticals position peaked at $491M in Q2 2015.
  • 414 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.